drugset / Trial / NCT01807234

Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine

NCT01807234

RandomizedCrossoverDouble-blindTreatment

Summary

The investigators propose to test the efficacy of ketorolac nasal spray versus sumatriptan nasal spray versus placebo for acute abortive therapy of migraine head pain as well as for migraine associated symptoms including nausea and allodynia.

Timeline

Start
2013-02
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketorolac Other / unclassified 31.5 mg Intranasal
Subject Sumatriptan Unknown 20 mg Intranasal

Indications